Brokerages expect Henry Schein, Inc. (NASDAQ:HSIC) to report sales of $2.52 billion for the current fiscal quarter, Zacks reports. Seven analysts have made estimates for Henry Schein’s earnings. The highest sales estimate is $2.56 billion and the lowest is $2.50 billion. Henry Schein reported sales of $3.28 billion in the same quarter last year, which would suggest a negative year over year growth rate of 23.2%. The business is expected to report its next quarterly earnings report on Tuesday, November 5th.

On average, analysts expect that Henry Schein will report full-year sales of $9.97 billion for the current fiscal year, with estimates ranging from $9.92 billion to $10.06 billion. For the next year, analysts anticipate that the company will report sales of $10.35 billion, with estimates ranging from $10.23 billion to $10.53 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Henry Schein.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, August 6th. The company reported $0.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.01. The company had revenue of $2.45 billion during the quarter, compared to the consensus estimate of $2.48 billion. Henry Schein had a net margin of 4.18% and a return on equity of 16.67%. The company’s revenue was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.04 EPS.

HSIC has been the subject of several recent research reports. Zacks Investment Research lowered Henry Schein from a “buy” rating to a “hold” rating and set a $76.00 price objective for the company. in a report on Wednesday, June 19th. Svb Leerink restated a “market perform” rating and issued a $70.00 target price (down previously from $75.00) on shares of Henry Schein in a research note on Wednesday, May 15th. William Blair lowered Henry Schein from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 7th. Leerink Swann downgraded Henry Schein from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $75.00 to $70.00 in a research note on Wednesday, May 15th. They noted that the move was a valuation call. Finally, Barrington Research reaffirmed a “buy” rating and set a $75.00 price target on shares of Henry Schein in a research note on Wednesday, August 7th. Seven analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $73.64.

Shares of Henry Schein stock traded up $1.94 on Friday, hitting $65.84. 1,468,567 shares of the company traded hands, compared to its average volume of 1,671,180. Henry Schein has a 12-month low of $56.58 and a 12-month high of $72.81. The company has a quick ratio of 0.95, a current ratio of 1.70 and a debt-to-equity ratio of 0.33. The company has a market cap of $9.28 billion, a PE ratio of 15.94, a PEG ratio of 2.42 and a beta of 0.86. The company has a 50-day moving average price of $63.08 and a 200 day moving average price of $64.48.

In other news, Director E Dianne Rekow sold 3,500 shares of the company’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $71.18, for a total transaction of $249,130.00. Following the completion of the sale, the director now owns 14,147 shares in the company, valued at approximately $1,006,983.46. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Steven Paladino sold 20,712 shares of the stock in a transaction dated Wednesday, June 19th. The shares were sold at an average price of $72.17, for a total value of $1,494,785.04. Following the transaction, the chief financial officer now directly owns 166,233 shares in the company, valued at approximately $11,997,035.61. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 54,766 shares of company stock worth $3,860,201. Corporate insiders own 1.06% of the company’s stock.

Several hedge funds have recently modified their holdings of HSIC. Cullen Frost Bankers Inc. acquired a new position in Henry Schein during the second quarter valued at approximately $36,000. CSat Investment Advisory L.P. raised its position in shares of Henry Schein by 115.6% in the first quarter. CSat Investment Advisory L.P. now owns 552 shares of the company’s stock valued at $33,000 after purchasing an additional 296 shares during the period. Ibex Wealth Advisors bought a new position in shares of Henry Schein in the second quarter valued at approximately $40,000. Parallel Advisors LLC lifted its stake in shares of Henry Schein by 67.4% in the first quarter. Parallel Advisors LLC now owns 586 shares of the company’s stock worth $35,000 after buying an additional 236 shares during the last quarter. Finally, Rational Advisors LLC lifted its stake in shares of Henry Schein by 1,012.3% in the first quarter. Rational Advisors LLC now owns 723 shares of the company’s stock worth $43,000 after buying an additional 658 shares during the last quarter.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Further Reading: How is a management fee different from a performance fee?

Get a free copy of the Zacks research report on Henry Schein (HSIC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.